ACCELERATE

Innovation in therapies for children

and adolescents with cancer.


OUR NAME IS OUR MISSION!

Find out more

16th Paediatric Strategy Forum on B7-H3

In collaboration with EMA

With the participation of FDA


29-30 October 2026

PARIS & ONLINE

WHY ACCELERATE?

children and adolescents are diagnosed with cancer each year worldwide. 50,000+ only in EU and US combined

die out of this condition in Europe each year. 15 EVERY DAY

Cause of death by disease in children >1 year in high-income countries

of children with cancer resistant to conventional treatment die

of delay until the same new medicine already approved for adults gets approved for children

long-term survivors of childhood cancer live in Europe today. 2/3 of them experience long-term health related problems

HOW TO ACCELERATE

  • ALADDIN: the new educational program on strategic and regulatory science in paediatric oncology drug development


    Find out more
  • FAIR trials

    Fostering Age Inclusive Research (FAIR) Trials

    To improve access for adolescents to new anti-cancer drugs and to make the drug development process more efficient

    Find out more
  • ACCELERATE Publications

    ACCELERATE Publications


    Find out more

NEWS

16th Paediatric Strategy Forum on B7-H3


29-30 October 2026
Paris & Online


Rescuing Drugs That are Discontinued in Adult Oncology Development for the Benefit of Children and Adolescents With Cancer – An ACCELERATE Multistakeholder Consensus


ASCPT De Rojas, T. et al. November 2023


Read it now